$OPK News

OPKO Health Issues Additional $125M Of Senior Secured Notes To KKR's HealthCare Royalty For Non-Dilutive Funding

OPKO Health: A Hold As Progress Continues

OPKO Health, Inc. (OPK) Q2 2026 Earnings Call Transcript

OPKO Health (NASDAQ:OPK) Posts Breakout Earnings Beat, Shares Surge 16% After-Hours

OPKO Health Raises FY2026 Sales Guidance from $530.000M-$560.000M to $560.000M-$585.000M vs $534.899M Est

OPKO Health Sees Q3 Sales $131.000M-$142.000M vs $134.650M Est

OPKO Health Q2 EPS $(0.01), Sales $163.500M Beat $131.233M Estimate

OPKO Health Subsidiary EirGen Pharma Expands Agreement With Nicoya Therapeutics To Commercialize RAYALDEE In China

Barrington Research Downgrades OPKO Health to Market Perform

OPKO Health Q1 2026 Earnings Call: Complete Transcript

OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript

OPKO Health Inc (NASDAQ:OPK) Misses Q1 Revenue Estimates, Shares Slide After Hours

OPKO Health Affirms FY2026 Sales Guidance of $530.000M-$560.000M vs $551.214M Est

OPKO Health Sees Q2 Sales $127.000M-$132.000M vs $136.329M Est

OPKO Health Q1 EPS $(0.07), Inline, Sales $124.200M Miss $130.514M Estimate

Opko Health Subsidiary ModeX Therapeutics Begins MDX2003 Clinical Trial With First Dosing For Relapsed Or Refractory B-Cell Lymphoma

OPKO Health, Inc. (OPK) Makes Progress on Game changing Covid-19 Treatment

OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19

OPKO Health's ModeX Therapeutics Says First Participants Dosed In Phase 1 Clinical Trial Evaluating MDX2301 For Prevention Of COVID-19

Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates